Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Newer inotropic agents.

D N Sharpe

    Methods and Findings in Experimental and Clinical Pharmacology
    |April 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    New inotropic agents are needed to improve heart contractility, as current treatments like digitalis have limitations. Amrinone shows promise as a potent, orally active alternative with fewer adverse effects for heart failure management.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Management of patients with unstable angina in a general cardiology unit.

    The New Zealand medical journal·1998
    Same author

    Left ventricular function in scleroderma.

    British journal of rheumatology·1996
    Same author

    Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure.

    American journal of kidney diseases : the official journal of the National Kidney Foundation·1994
    Same author

    Cholesterol-lowering and blood pressure effects of immune milk.

    The American journal of clinical nutrition·1994
    Same author

    The heart of the matter.

    New Zealand health & hospital·1992
    Same author

    Cardiovascular disease in patients with end-stage renal failure.

    Australian and New Zealand journal of medicine·1992
    Same journal

    [Proceedings of the XVIII TASPE Seminar, Granada, Spain, 4-5 February 2010].

    Methods and findings in experimental and clinical pharmacology·2011
    Same journal

    [Treatment algorithm for gastrointestinal graft-versus-host disease].

    Methods and findings in experimental and clinical pharmacology·2011
    Same journal

    [Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].

    Methods and findings in experimental and clinical pharmacology·2011
    Same journal

    [Classification of chronic graft-versus-host disease].

    Methods and findings in experimental and clinical pharmacology·2011
    Same journal

    [Pegfilgrastim in hematopoietic stem cell transplantation].

    Methods and findings in experimental and clinical pharmacology·2011
    Same journal

    [Allogeneic transplantation in multiple myeloma patients: results and recommendations in February 2010].

    Methods and findings in experimental and clinical pharmacology·2011
    See all related articles

    Area of Science:

    • Pharmacology
    • Cardiology
    • Drug Discovery

    Background:

    • Impaired myocardial contractility reduces cardiac output, triggering detrimental compensatory mechanisms.
    • Current drug treatments include inotropic agents, diuretics, and vasodilators to manage heart failure symptoms.
    • Digitalis, a traditional inotropic agent, has modest efficacy and significant toxicity concerns.

    Purpose of the Study:

    • To address the need for novel inotropic agents with improved potency, oral bioavailability, long-term efficacy, and reduced adverse effects.
    • To evaluate alternative therapeutic strategies for managing heart failure beyond digitalis.
    • To explore non-adrenergic inotropic agents as potential treatments.

    Main Methods:

    • Review of existing literature on inotropic agents and heart failure management.

    Related Experiment Videos

  • Evaluation of beta-adrenergic agonists and their limitations, including tolerance development.
  • Assessment of non-adrenergic inotropic agents, focusing on amrinone.

    • Main Results:

    • Beta-adrenergic agonists show limited long-term efficacy due to receptor downregulation and tolerance.
    • Amrinone emerges as a promising non-adrenergic inotropic agent.
    • The precise mechanism of action for amrinone remains to be elucidated.

    Conclusions:

    • There is a significant clinical need for safer and more effective inotropic agents.
    • Amrinone represents a promising candidate for heart failure treatment, warranting further investigation.
    • Further research is required to understand amrinone's mechanism of action and optimize its therapeutic application.